| Biotechnology Industry | Healthcare Sector | Maria Forss CEO | CBOE Exchange | SE0013647385 ISIN |
| SE Country | 695 Employees | - Last Dividend | 10 Jan 2020 Last Split | - IPO Date |
BICO Group AB (publ) is recognized as a pioneering entity in the bioconvergence industry, demonstrating a broad geographical presence across North America, Europe, Asia, and various global markets. The company's operations are segmented into Bioprinting, Biosciences, and Bioautomation, reflecting its comprehensive approach towards modernizing life sciences and healthcare sectors. Initially established as Cellink AB (publ), the organization underwent a rebranding to BICO Group AB (publ) in August 2021, marking a significant milestone since its inception in 2016. Based in Gothenburg, Sweden, BICO Group is committed to advancing medical, pharmaceutical, and cosmetic industries by integrating cutting-edge technologies and fostering innovation within bioconvergence.
This segment emphasizes products, solutions, and services dedicated to supporting 3D cell culture and 3D printing technologies. BICO Group's bioprinting offerings are designed to expedite research and development processes, enabling the creation of complex biological structures that can mimic natural tissues, thereby facilitating advancements in tissue engineering and regenerative medicine.
In the Biosciences segment, BICO Group provides a variety of instruments tailored for efficient cell handling, management of rare samples, and seamless transfer of liquids and reagents. The company also supplies platforms for downstream analysis, catering to the needs of researchers and professionals in biotechnological and pharmaceutical sectors. Through these tools, BICO Group aids in streamlining experimental workflows and enhancing the accuracy of scientific investigations.
The Bioautomation segment offers comprehensive products and services that encompass precision dispensing, advanced sample preparation, multiplex analysis, and assay miniaturization. Additionally, it addresses the needs of the diagnostic and medical device manufacturing industries with solutions that optimize efficiency and reliability in laboratory processes. BICO Group's bioautomation solutions are critical for organizations aiming to achieve high-throughput screening and diagnostic testing with utmost precision.